(Total Views: 241)
Posted On: 03/30/2022 10:48:44 AM
Post# of 1418
Enanta doesn't even have phase I data and were granted fast track
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 - March 29, 2022
https://finance.yahoo.com/news/enanta-pharmac...00026.html
They just dosed their first patient last month. Why would this $1.4B company bother since some said the pandemic is over?
Everest, a billion dollar Chinese company wants in on the 3CL action too
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
"Under the deal, Everest would pay a license fee of $2.5 million, potential development milestone payments of up to $107 million, and sales milestone payments up to US$105 million."
https://www.thebambooworks.com/everest-boosts...ded-field/
But they have to do the trials first including phase 1
https://www.everestmedicines.com/Pipeline.aspx
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 - March 29, 2022
https://finance.yahoo.com/news/enanta-pharmac...00026.html
They just dosed their first patient last month. Why would this $1.4B company bother since some said the pandemic is over?
Everest, a billion dollar Chinese company wants in on the 3CL action too
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
"Under the deal, Everest would pay a license fee of $2.5 million, potential development milestone payments of up to $107 million, and sales milestone payments up to US$105 million."
https://www.thebambooworks.com/everest-boosts...ded-field/
But they have to do the trials first including phase 1
https://www.everestmedicines.com/Pipeline.aspx
(1)
(0)
